Top 10 Rotigotine (Neupro) Generic Manufacturers in Mexico
The pharmaceutical industry in Mexico has witnessed substantial growth over the past decade, particularly in the generic drugs sector. As of 2022, the Mexican generic pharmaceutical market was valued at approximately $3.5 billion, with projections to reach $5 billion by 2025. Rotigotine, marketed under the brand name Neupro, is a key drug in treating Parkinson’s disease and restless legs syndrome, contributing to the growing demand for affordable medication. The rise in chronic diseases and the increasing acceptance of generics among healthcare providers and patients have accelerated the presence of manufacturers in this competitive landscape.
1. Laboratorios PiSA
Laboratorios PiSA is one of the leading generic manufacturers in Mexico, with a significant production capacity of over 1 billion units annually. The company holds a notable market share of 7% in the generic pharmaceutical sector and has been actively involved in the production of Rotigotine, ensuring high-quality standards that meet both national and international regulations.
2. Genomma Lab Internacional
Genomma Lab is a prominent player in the Mexican pharmaceutical landscape, with a revenue exceeding $700 million in 2022. The company has diversified its portfolio to include generics, including Rotigotine, and holds approximately 5% of the market share. Genomma Lab’s commitment to innovation and quality has bolstered its position in the industry.
3. Farmacéuticos Synthesis
Farmacéuticos Synthesis specializes in generic formulations and has expanded its operations to produce Rotigotine. With a production volume exceeding 500 million units annually, the company has captured around 3% of the market share in the generics segment, focusing on cost-effective solutions for chronic disease management.
4. Laboratorios Sanfer
Laboratorios Sanfer is recognized for its extensive range of generic medications, including Rotigotine. The company reported a revenue of approximately $600 million in 2022 and holds around 4% of the market share. Its strategic partnerships with healthcare providers have enhanced its distribution capabilities across the country.
5. Neolpharma
Neolpharma has made significant strides in the Mexican pharmaceutical market, with a focus on generics. The company produces more than 300 million units of generic drugs annually, including Rotigotine variants. Neolpharma commands a market share of about 3.5%, leveraging its robust research and development capabilities.
6. Grupo Farmacéutico Somar
Grupo Farmacéutico Somar is a key contributor to the Mexican generics market, with a production capacity of approximately 400 million units. The company has focused on expanding its portfolio to include Rotigotine, and currently holds a market share of around 2.5%. Somar’s emphasis on quality assurance has strengthened its reputation in the sector.
7. Laboratorios Asofarma
Asofarma has established itself as a credible player in the generics market, producing over 250 million units annually, including Rotigotine. The company holds approximately 2% market share and is known for its commitment to affordable healthcare solutions, catering primarily to the Mexican population.
8. Laboratorios Grin
Laboratorios Grin focuses on the development and manufacturing of generic medications, including Rotigotine. With a production volume of over 200 million units, Grin has captured about 1.5% market share in the generics segment. The company is focused on expanding its distribution channels to reach more healthcare providers.
9. Farmaceútica NACIONAL
Farmaceútica NACIONAL has been a longstanding player in the Mexican market, producing a range of generic drugs, including Rotigotine. The company has an annual production capacity of approximately 150 million units and holds a market share of about 1.2%. Their focus on regulatory compliance has positioned them favorably in the competitive landscape.
10. Laboratorios Liconsa
Laboratorios Liconsa has ventured into the generics market, producing Rotigotine among other drugs. With an estimated annual production of 100 million units, the company maintains a market share of around 1%. Liconsa is committed to enhancing access to essential medications in Mexico, making it a key player in the sector.
Insights and Future Trends
The Mexican generic pharmaceutical market is projected to continue its robust growth, fueled by increasing demand for chronic disease management solutions and cost-effective medications. In 2022, the market for generics constituted nearly 80% of the total pharmaceutical sales in Mexico, highlighting a growing preference among consumers and healthcare providers for affordable options. Furthermore, advancements in manufacturing technologies and regulatory frameworks are expected to enhance production efficiencies and quality assurance. As the market matures, collaborations between manufacturers and healthcare providers will be crucial for expanding access to essential medications, including Rotigotine, thereby shaping the future landscape of the pharmaceutical sector in Mexico.
Related Analysis: View Previous Industry Report
